ArticleJournal of molecular histology2026
Arctiin activates CB2R to regulate the TRAF6-STAT1/6 pathway maintain macrophage M1/M2 homeostasis.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune rejection after liver transplantation remains a major challenge impacting the long-term survival of liver transplant recipients. Inhibiting macrophage M1 polarization exerts a positive effect on alleviating post-transplant immune rejection. Arctiin, an active component derived from traditional Chinese medicine, may suppress macrophage M1 polarization by inhibiting the release of pro-inflammatory cytokines. This study employed experimental techniques including ELISA, double-label flow cytometry, Western blot analysis, and cellular immunofluorescence to investigate the potential mechanism underlying the effect of arctiin on macrophage M1/M2 phenotypic switching in vitro. Results demonstrated that arctiin promoted the conversion of M0 macrophages to the M2 phenotype, significantly downregulated the levels of pro-inflammatory cytokines IL-6 and TNF-α, inhibited the expression of the M1 macrophage marker inducible nitric oxide synthase (iNOS), and reduced the proportion of M1-type macrophages. Furthermore, arctiin notably enhanced STAT6 phosphorylation and TRAF6 protein expression in M1 macrophages while suppressing STAT1 phosphorylation. However, these beneficial effects of arctiin were significantly reversed by a CB2R antagonist. Additional experiments showed that a CB2R agonist exerted similar effects to arctiin. Treatment with a TRAF6 inhibitor abrogated the inhibitory effect of arctiin or the CB2R agonist on macrophage M1 polarization, increased STAT1 phosphorylation, and decreased STAT6 phosphorylation. In conclusion, this study indicates that arctiin can activate CB2R and exert anti-inflammatory effects through the TRAF6-STAT1/6 pathway, thereby promoting the phenotypic switch of macrophages from M1 to M2.
Indexed as
Identifiers
42399521What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.